Quick Answer
Theravance Biopharma, Inc. reported Stockholders Equity of $296.72 million for fiscal year 2025.
Theravance Biopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $296.72M | +69.0% |
| 2024 | $175.54M | -17.6% |
| 2023 | $213.00M | -51.8% |
| 2022 | $441.80M | +230.5% |
| 2021 | -$338.57M | -11.5% |
| 2020 | -$303.75M | -35.7% |
| 2019 | -$223.84M | -333.9% |
| 2018 | -$51.59M | -144.8% |
| 2017 | $115.18M | -67.1% |
| 2016 | $350.23M | +44.1% |
| 2015 | $243.06M | -16.1% |
| 2014 | $289.79M | +1801.1% |
| 2013 | -$17.04M | -143.7% |
| 2012 | -$6.99M | +95.0% |
| 2011 | -$140.72M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $232.68M | +25.3% | +3.5% |
| June 30, 2025 | $224.85M | +16.1% | +35.5% |
| March 31, 2025 | $165.98M | -19.0% | -5.4% |
| December 31, 2024 | $175.54M | -17.6% | -5.4% |
| September 30, 2024 | $185.65M | -24.6% | -4.1% |
| June 30, 2024 | $193.69M | -30.9% | -5.5% |
| March 31, 2024 | $204.87M | -44.7% | -3.8% |
| December 31, 2023 | $213.00M | -51.8% | -13.5% |
- Theravance Biopharma, Inc. showed an increase of +69.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Theravance Biopharma, Inc.’s stockholders equity has grown by 310.9% (from -$140.72 million to $296.72 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: